Advanced Diagnostics Using RNA/Protein Fusion Technology

Information

  • Research Project
  • 6484914
  • ApplicationId
    6484914
  • Core Project Number
    R44AI046106
  • Full Project Number
    2R44AI046106-03
  • Serial Number
    46106
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/1999 - 26 years ago
  • Project End Date
    4/30/2003 - 22 years ago
  • Program Officer Name
    SONG, MIN-KYUNG H.
  • Budget Start Date
    5/1/2002 - 23 years ago
  • Budget End Date
    4/30/2003 - 22 years ago
  • Fiscal Year
    2002
  • Support Year
    3
  • Suffix
  • Award Notice Date
    4/24/2002 - 24 years ago
Organizations

Advanced Diagnostics Using RNA/Protein Fusion Technology

The objective of this project is to develop advanced diagnostic and therapeutic monitoring systems for agents involved in allergy and inflammation. A key initiative in NIAID programs for Healthy People 2010 is the development of tools for drug discovery and monitoring allergy and inflammation that are associated with infectious disease and chronic disabling conditions. Cytokines and chemokines are mediators (or surrogate markers) of these disease processes. In this program, a novel immunoglobulin-like scaffold has been developed as an antibody mimic. From a large random library consisting of 10313-10e14 distinct members, binding proteins were rapidly selected in vitro against key mediators by inflammatory or allergic processes. Antibody mimics to a minimum of 5 cytokine or chemokine targets were selected and will be further evaluated for performance characteristics such as affinity, specificity, epitope mapping, and ability to function on a solid phase surface. If needed, binding proteins can be improved by affinity maturation, and PCR mutagenesis. The resulting antibody-mimics will be used for the development of a prototype addressable protein chip for detection of these markers in a variety of experimental samples. This multiplex microarray will be validated for the detection and quantification of cytokines and/or chemokines in culture supernatants, biological fluids, cells, or tissues. PROPOSED COMMERCIAL APPLICATIONS: This technology provides a powerful alternative to monoclonal antibodies and phage display mediated production of antibodies or fragments thereof. These unique protein binders will be incorporated into an addressable multiplex array for the high throughput analysis of samples from culture supernatants, biological fluids or cells for drug discovery and diagnostic applications.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R44
  • Administering IC
    AI
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    358326
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:358326\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PHYLOS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    LEXINGTON
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02421
  • Organization District
    UNITED STATES